Please wait while we open this resource.
K
Clinical reviews
GASTROINTESTINAL ADVERSE EFFECTS
Endocrinology
PDF12 pages964 KB
The advent of incretin therapies has transformed obesity management, particularly in patients with insulin resistance and related complications. Medications such as exenatide, liraglutide, and semaglutide have shown efficacy in weight loss and improving insulin sensitivity. However, with their extensive use, safety concerns, particularly gastrointestinal adverse effects, have emerged. This document aims to provide insights into these adverse effects and their implications for clinical practice.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
ADA Consensus Report: MASLD in People With Diabetes
Same clinical topic · Endocrinology
2025 ADA Diabetes Care Standards Updates
Same clinical topic · Endocrinology
METFORMIN―MECHANISMS OF ITS GLYCEMIA-REDUCING EFFECT
Same clinical topic · Endocrinology
SYNDROME OF INAPPROPRIATE ANTIDIURESIS: FROM PATHOPHYSIOLOGY TO MANAGEMENT
Same clinical topic · Endocrinology
GLYCEMIC EMERGENCIES
Same clinical topic · Endocrinology
DIAGNOSIS AND MANAGEMENT OF CENTRAL DIABETES INSIPIDUS IN ADULTS
Same clinical topic · Endocrinology
ANTI-OBESITY DRUGS: COMPREHENSIVE REVIEW AND EMERGING THERAPIES
Same clinical topic · Endocrinology
DRUG DELIVERY SYSTEMS FOR THYROID DISEASE TREATMENT: A MINI REVIEW ON CURRENT THERAPIES AND ALTERNATIVE APPROACHES
Same clinical topic · Endocrinology
OTHER BENEFITS OF CONTROLLING CARBOHYDRATES
Same clinical topic · Endocrinology